Shake, Forgive me if I misquote you or GC or tw
Post# of 30028
Forgive me if I misquote you or GC or twist your words, but for a diagnostic test that is supposed to commercialize this year it is alarming to me that "various companies had previously known about LymPro and was wondering what happened to it". To me this points to idea that LymPro may not be a huge hit as we hope for, but a low revenue test with limited not widespread application. Pharmaceutical companies, scientists, or other medical professions should know about this test and be excited for its release as opposed to wondering what had happened to it. Again I hope this is just a concern of mine, and will be alleviated when further data and partnership news is released and catches the attention of everyone else. The next few weeks/month will definitely be an exciting time for AMBS.